β-arrestin2在非小细胞肺癌患者血清中表达的临床意义  

The Clinical Significance of β-arrestin 2 Expression in the Serum of Non-small Cell Lung Cancer Patients

作　　者：吴正清[1] 童文侠[2] 谭子辉[1] 王思愚[1] 林鹏[1] 

机构地区：[1]中山大学肿瘤防治中心胸科,华南肿瘤学国家重点实验室,广州510060 [2]中山大学肿瘤防治中心妇科,广州510060

出　　处：《中国肺癌杂志》2011年第6期497-501,共5页Chinese Journal of Lung Cancer

基　　金：中山大学临床医学研究5010计划(No.200744)基金资助~~

摘　　要：背景与目的非小细胞肺癌(non-small cell lung cancer,NSCLC)是肺癌中最常见的类型,具有较高的发病率及病死率。β-arrestin2是一种介导受体脱敏的重要可溶性蛋白质,在G蛋白偶联受体介导的信号转导中具有重要调节作用。本研究旨在探讨β-arrestin2在NSCLC患者血清中的表达,并探讨其临床意义。方法选取留有血清标本的2005年1月-2006年12月于中山大学肿瘤防治中心治疗并确诊的NSCLC患者67例及正常体检者20例,采用ELISA方法测定选取血清标本中β-arrestin2蛋白的表达情况,并对相应病例的临床及随访资料进行回顾性分析。结果 NSCLC患者组别均较正常人组别血清β-arrestin2浓度低(P<0.001,P<0.001,P<0.001);同时I期患者组别较III期、IV期患者组别血清β-arrestin2浓度高(P<0.001,P<0.001);而III期与IV期患者组别血清β-arrestin2浓度无差异(P=0.273)。Kaplan-Meier分析显示β-arrestin2高表达患者较中、低表达患者预后更好(P<0.001,P<0.001)。COX回归分析显示,β-arrestin2浓度和肿瘤分期对预后具有明显意义(P=0.003,P=0.004)。结论β-arrestin2在正常人和NSCLC患者、不同病理分期NSCLC患者血清中浓度有差异。血清β-arrestin2浓度影响NSCLC患者预后。Background and objective Non-small cell lung cancer （NSCLC） with high morbidity and mortality is the most common types of lung cancer. beta-arrestin 2 is a kind of soluble protein regulating signal transduction mediated by G protein coupling receptor. The aim of this research is to evaluate the clinical significance of β-arrestin 2 expression in the serum of NSCLC patients. Methods The clinical and follow-up data of 20 healthy candidates and 67 patients diagnosed with NSCLC in Sun Yat-sen University Cancer Center from January 2005 to December 2006 was retrospectively analyzed. ELISA was applied to detect the expression of beta-arrestin 2. Results The serum level of β-arrestin 2 in NSCLC patients were all sig-nifically lower than those in healthy controls （P〈0.001, P〈0.001, P〈0.001）. The serum level of β-arrestin 2 in stage I NSCLC patients were higher than those in stage III as well as in stage IV （P〈0.001, P〈0.001）. No statistical difference of β-arrestin 2’ serum level was found between with stage III and stage IV patients （P=0.273）. Univariate prognostic factor analyzed by Kaplan-Meier method indicated patients’ prognosis with high serum level of β-arrestin 2 was better than patients with low and middle （P〈0.001, P〈0.001）. The serum level of β-arrestin 2 and the stage of NSCLC signally affected prognosis in COX regres-sion model （P=0.003, P=0.004）. Conclusion The serum level of β-arrestin 2 had significant difffrence between NSCLC pa-tients and healthy controls, likewise between the early and advanced NSCLC patients. The serum level of β-arrestin 2 affected NSCLC patients’ prognosis.

关 键 词：β-arrestin2 肺肿瘤 预后因素 

分 类 号：R734.2[医药卫生—肿瘤]